ADMA Adma Biologics, Inc. - 8-K

Item 5.07

Submission of Matters to a Vote of Security Holders

ADMA Biologics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 2, 2026. At the Annual Meeting, the following matters
were submitted to a vote of stockholders:

1.

The election of two nominees to serve as Class I directors until the Company’s 2029 Annual Meeting of Stockholders and until such director’s successor is duly elected
and qualified, or such director’s earlier resignation, removal or death;

2.

The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; and

3.

The approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (“Say-on-Pay”).

At the close of business on April 8, 2026, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 232,324,283 shares of
the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The holders of 199,267,547 shares of the Company’s common stock, $0.0001 par value per share, were represented virtually or by proxy at the Annual Meeting,
constituting a quorum.

At the Annual Meeting, (i) the two Class I directors were elected, (ii) the appointment of the Company’s independent registered public accounting firm for the fiscal
year ending December 31, 2026 was ratified, and (iii) the Say-on-Pay proposal was approved.

Proposal No. 1   — Election of the Class I
Directors

The vote with respect to the election of each of the directors was as follows:

Nominee

For

Withheld

Broker Non-Votes

Alison C. Finger

156,849,830

19,376,842

23,040,875

Eduardo Rene Salas

171,947,523

Shares

4,279,149

Shares

23,040,875

Shares

Proposal No. 2 — Ratification of the
Appointment of Independent Registered Public Accounting Firm

The vote with respect to the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December
31, 2026 was as follows:

For

Against

Abstain

198,655,040

Shares

329,056

Shares

283,451

Shares

Proposal No. 3 — Approval of the Say-on-Pay
Proposal

The vote with respect to the approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers was as follows:

For

Against

Abstain

Broker Non-Votes

168,169,866

Shares

7,730,690

Shares

326,116

Shares

23,040,875

Shares